1 citations · 2 across the 6 of their papers we have counts for
8 papers
Days Alive at Home vs Out of Hospital: Why the Difference Matters for Trial Endpoints
Letao Yuan, Sarah N. Dawson, David S. Robertson +5
Days Alive and Out of Hospital (DAOH) and Days Alive at Home (DAH) are increasingly used as patient-centred primary outcomes in perioperative trials, and a recent editorial has adv…
Ready for the Clinic? A Survey of Open-Source Software for Response-Adaptive Randomization in Clinical Trials
Stina Zetterstrom, David S. Robertson, Sofía S. Villar
Response-adaptive randomization (RAR) modifies treatment allocation probabilities during a clinical trial as response/outcome data accumulate, with the aim of improving patient ben…
Introducing precision-weighted bias as a performance measure to inform the inclusion of adaptive designs in meta-analysis
Martin Law, David S. Robertson, Sofia S. Villar +4
We propose a novel, intuitive measure of statistical performance: precision-weighted bias. Precision-weighted bias is defined as the unconditional bias of an estimator weighted by…
Operationalizing Allocation Probability Tests: Practical Guidance on Optimized Implementation for Power and Robustness
Stina Zetterstrom, David S. Robertson, Thomas Jaki +1
Recently, a new testing approach for response-adaptive clinical trials was proposed based on the allocation probabilities (AP) rather than the outcome data. While original work on…
Optimal weighted tests for replication studies and the two-trials rule
David S. Robertson, Thomas Jaki
Replication studies for scientific research are an important part of ensuring the reliability and integrity of experimental findings. In the context of clinical trials, the concept…
A comparison of approaches to incorporate patient-selected and patient-ranked outcomes in clinical trials
David S. Robertson, Thomas Jaki
A key aspect of patient-focused drug development is identifying and measuring outcomes that are important to patients in clinical trials. Many medical conditions affect multiple sy…
Confidence intervals for adaptive trial designs II: Case study and practical guidance
David S. Robertson, Thomas Burnett, Babak Choodari-Oskooei +4
In adaptive clinical trials, the conventional confidence interval (CI) for a treatment effect is prone to undesirable properties such as undercoverage and potential inconsistency w…
Confidence intervals for adaptive trial designs I: A methodological review
David S. Robertson, Thomas Burnett, Babak Choodari-Oskooei +4
Regulatory guidance notes the need for caution in the interpretation of confidence intervals (CIs) constructed during and after an adaptive clinical trial. Conventional CIs of the…